Gene Solutions Debuts ctDNA Oncology Portfolio in Türkiye
Gene Solutions announced its entry into the Turkish market at the 2nd International Hereditary Cancers Congress (IHCC) held Feb. 5–8, 2026 in Antalya, partnering with ATC Genomics to present RWE from one of Asia’s largest cohorts (n=12,281) evaluating its SPOT-MAS multi-cancer early detection assay. The company highlighted clinical performance—sensitivity ~78.2%, specificity 99.8%, tumor-of-origin ~82%—and showcased K-4CARE genomic/transcriptomic profiling and MRD monitoring for high-risk populations.
Key Points
- 1Presented one of Asia’s largest RWE cohorts (n=12,281) evaluating SPOT-MAS MCED.
- 2Demonstrated high analytical performance: sensitivity 78.2%, specificity 99.8%, tumor-of-origin accuracy 82%.
- 3Enables clinicians to integrate ctDNA-based screening, profiling, and MRD surveillance for high-risk patients.
Scoring Rationale
Strong clinical RWE and peer-reviewed validation drive credibility; commercial rollout and limited methodological innovation constrain impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
